CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
atorvastatin +1 moredrug
Likely dose
atorvastatin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00965185
NCT00965185N/ACompleted
CompareCT.gov

Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients

Massachusetts General Hospital·interventional·Posted Aug 25, 2009·Updated Dec 11, 2017

In Brief

A clinical study evaluating atorvastatin and Placebo for Cardiovascular Disease and 5 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function. In addition to known cholesterol-lowering and C-reactive protein lowering effects, immunomodulatory effects of statins will lead to a shift from pro-inflammatory monocyte and T cell subsets to less atherogenic subpopulations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 25, 2009
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.9 years ago

Interventions

atorvastatindrug

20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.

Placebodrug

Placebo